文献速递前列腺癌

局限性前列腺癌当代治疗方式的长期肿瘤学结局:基于人群的前瞻性队列研究

Long-term oncological outcomes from a prospective cohort of patients with localised prostate cancer.
PubMed 文献 · BJU Int · 2026-08-12

CEASAR研究前瞻性纳入2011至2012年美国2604例临床局限性前列腺癌患者,按预后分层比较手术、EBRT、近距离放疗和主动监测的长期结局。所有策略10年前列腺癌特异性死亡率均低(有利组≤1.5%),不利组手术与EBRT无PCSM差异,但手术总生存优于EBRT,可能反映残余混杂。

要点

  • 有利预后组所有治疗策略10年PCSM累积发生率≤1.5%,进展无差异。
  • 不利预后组EBRT与更差OS相关(HR 2.8,95%CI 1.9-4.3),PCSM无调整差异。
  • 手术OS优势可能反映基线健康和治疗选择的残余混杂。

核心结论

  • 当代治疗方式下,包括主动监测在内的所有策略10年前列腺癌死亡风险均低。
  • 手术总生存优势可能反映基线健康和治療选择的残余混杂。
  • 局限性前列腺癌共享决策应重视患者价值观和合并症。

研究设计与样本

  • CEASAR研究为基于美国人群的前瞻性队列,2011至2012年入组临床局限性前列腺癌患者。
  • 共纳入2604例男性,73%白人、15%黑人、7%西班牙裔。
  • 按预后分层:有利预后(cT1-T2a/bN0M0,PSA≤20 ng/mL,Grade Group 1-2)和不利预后(cT2cN0M0,PSA 20-50 ng/mL,或Grade Group 3-5)。
  • 主要结局为前列腺癌特异性死亡率、进展至晚期疾病的复合终点和总生存。
  • 采用Cox回归和Fine-Gray模型调整人口学和临床协变量。

主要发现

  • 有利预后组中,与手术相比,EBRT(HR 1.5,95%CI 1.1-2.1,P<0.01)、近距离放疗(HR 2.1,95%CI 1.3-3.3,P<0.01)和主动监测(HR 1.5,95%CI 1.1-2.1,P=0.02)与更高的全因死亡率相关。
  • 有利预后组所有五种策略的10年PCSM累积发生率≤1.5%,且进展无差异。
  • 不利预后组中,EBRT与更差OS相关(HR 2.8,95%CI 1.9-4.3,P<0.01)。
  • 不利预后组PCSM无调整差异(手术后10年累积发生率3.5% vs EBRT后8.8%),进展无差异。

关键数值与推荐

  • 有利预后定义:cT1-T2a/bN0M0,PSA≤20 ng/mL,Grade Group 1-2。
  • 不利预后定义:cT2cN0M0,PSA 20-50 ng/mL,或Grade Group 3-5。
  • 有利预后组10年PCSM累积发生率≤1.5%(所有五种策略)。
  • 不利预后组10年PCSM累积发生率:手术3.5%,EBRT 8.8%。

临床怎么用

  • 局限性前列腺癌共享决策应结合患者价值观和合并症,而非仅依据肿瘤学结局。
  • 对有利预后患者,主动监测是合理选择,10年PCSM风险低。
  • 手术与放疗的总生存差异需谨慎解读,可能受残余混杂影响。

局限性

  • OS差异可能反映基线健康和治療选择的残余混杂。
  • 原文未报告其他局限性信息。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To report long-term oncological outcomes for men with clinically localised prostate cancer (PCa) treated with contemporary modalities in a population-based United States cohort. PATIENTS AND METHODS: The Comparative Effectiveness Analysis of Surgery and Radiation (CEASAR) study prospectively enrolled men with clinically localised PCa from 2011 to 2012. Patients were stratified into two groups: favourable prognosis (clinical T stage [cT]1-T2a/bN0M0, prostate-specific antigen [PSA] level ≤ 20 ng/mL, Grade Group 1-2) and unfavourable prognosis (cT2cN0M0, PSA level 20-50 ng/mL, or Grade Group 3-5). Main outcomes were PCa-specific mortality (PCSM), composite progression to advanced disease (metastasis, PCSM event, or systemic therapy), and overall survival (OS). Cox regression models adjusted for demographic and clinical covariates. RESULTS: Of the 2604 men included, 73% were White, 15% Black, and 7% Hispanic. All hazard ratios (HRs) were adjusted for demographic and clinical covariates using multivariable Cox and Fine-Gray models. In the favourable group, compared with surgery, external beam radiotherapy (EBRT; HR 1.5, 95% confidence interval [CI] 1.1-2.1, P < 0.01), brachytherapy (HR 2.1, 95% CI 1.3-3.3, P < 0.01), and active surveillance (HR 1.5, 95% CI 1.1-2.1, P = 0.02) were associated with higher all-cause mortality; the 10-year cumulative incidence of PCSM was ≤1.5% for all five strategies, and progression did not differ. In the unfavourable group, EBRT was associated with worse OS (HR 2.8, 95% CI 1.9-4.3, P < 0.01), with no adjusted differences in PCSM (10-year cumulative incidence 3.5% after surgery vs 8.8% after EBRT) or progression across treatments. CONCLUSION: In this population-based cohort treated with contemporary modalities, the 10-year risk of PCa death was low across all treatment strategies, including active surveillance. OS differences favouring surgery likely reflect residual confounding from baseline health and treatment selection. These findings underscore the importance of patient values and comorbidities in shared decision-making for localised PCa.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Baskin AS, Hoffman KE, Penson DF, et al. Long-term oncological outcomes from a prospective cohort of patients with localised prostate cancer. BJU Int. 2026. PMID: 42581832. doi:10.1111/bju.70410

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。